source
- Latus Bio raises $97 million to advance gene therapies for Huntington’s and Batten diseaseLatus Bio announced closing a $97 million Series A round, including a $43 million extension to a prior $54 million raise. Funding was led by 8VC and included eight other investors such as DCVC Bio…
- UCB to buy Candid Therapeutics for up to $2.2 billion, targeting bispecific antibodies for autoimmune diseaseUCB announced a deal to acquire Candid Therapeutics, a startup focused on bispecific antibody drugs, for an upfront payment of $2 billion with up to $200 million in future milestones. The transacti…